Systematic identification of immunodominant CD4+ T cell responses to HpaA in Helicobacter pylori infected individuals.
Systematic identification of immunodominant CD4+ T cell responses to HpaA in Helicobacter pylori infected individuals.
复制标题
系统鉴定幽门螺杆菌感染个体中对 HpaA 的免疫显性 CD4 T 细胞反应。
DOI：
10.18632/oncotarget.11092
复制
发表时间：
2016-08-23
期刊：
影响因子：
--
通讯作者：
Wu C
中科院分区：
文献类型：
--
作者：
Hu J;Chen L;Yang W;Li B;Sun H;Wei S;He Y;Zhao Z;Yang S;Zou Q;Chen W;Guo H;Wu C
在小鼠中，抗原特异性CD 4 + T细胞应答对于针对幽门螺杆菌（H. pylori，H. pylori）。神经氨酸乳糖结合血凝素（HpaA）免疫小鼠可保护小鼠免受H。pylori感染的CD 4 + T细胞依赖性的方式。然而，关于人CD 4 + T细胞对HpaA的应答仍有许多不清楚的地方。我们进行了系统的研究，以探讨免疫显性，HpaA特异性的CD 4 + T细胞反应在H。pylori感染者。我们发现，HpaA特异性CD 4 + T细胞反应的变化显着的幅度，并具有广泛的表位特异性。重要的是，主要的反应集中在两个区域：HpaA 76 -105和HpaA 130 -159。HLA-DRB 1 *0901限制性HpaA 142 -159特异性CD 4 + T细胞应答是群体水平上最主要的免疫显性应答。免疫优势表位HpaA 142 -159是天然存在的，并且高度保守。我们还证实了HpaA特异性CD 4 + T细胞应答的强度与H.幽门感染这一研究将有助于抗H.幽门感染
In mice, antigen-specific CD4+ T cell response is indispensible for the protective immunity against Helicobacter pylori (H. pylori). It has been demonstrated that neuraminyllactose-binding hemagglutinin (HpaA) immunization protected mice from H. pylori infection in a CD4+ T cell dependent manner. However, much remains unclear concerning the human CD4+ T cell responses to HpaA. We conducted a systematic study here to explore the immunodominant, HpaA-specific CD4+ T cell responses in H. pylori infected individuals. We found that HpaA-specific CD4+ T cell responses varied remarkably in their magnitude and had broad epitope-specificity. Importantly, the main responses focused on two regions: HpaA76-105 and HpaA130-159. The HLA-DRB1*0901 restricted HpaA142-159 specific CD4+ T cell response was the most immunodominant response at a population level. The immunodominant epitope HpaA142-159 was naturally presented and highly conserved. We also demonstrated that it was not the broad peptide specificity, but the strength of HpaA specific CD4+ T cell responses associated with gastric diseases potentially caused by H. pylori infection. Such investigation will aid development of novel vaccines against H. pylori infection.